INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

Executives from the South Korean bioventure firm Oscotec talk to Scrip about the significance of the recent license agreement for a third-generation EGFR inhibitor by partner Yuhan, and extolled the company’s other core pipeline products, which include novel candidates for rheumatoid arthritis and cancer.

South Korean bioventure Oscotec Inc. is taking a two-pronged approach to the global development of its novel drugs: using open innovation agreements with domestic companies for early-stage drug compound candidates and directly licensing out its more advanced development-stage drug candidates to global pharma firms.

"We can't take all the pipeline [products forward]

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.